AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04783662 — intervention group
Intervention type: DEVICE
Intervention: Intraoperative frontal electroencephalogram
Description: Intra operative frontal electroencephalogram registration with 1 age adjusted Minimum Anesthetic Concentration of Sevoflurane
Study NCT06078670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL218
Description: Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
Study NCT04626141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
Study NCT04626141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be dispensed as a 30-day supply of disposable pen injections.
Study NCT06181045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Administered orally.
Study NCT06181045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3410738
Description: Administered orally.
Study NCT06181045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT06181045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT05279040 — intervention group
Intervention type: DRUG
Intervention: Trikafta
Description: Elexacaftor/Tezacaftor/Ivacaftor combination therapy
Study NCT05358405 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Müller maneuver
Description: The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
Study NCT05644340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speed 8 (Fast balancing gas flow)
Description: General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 8. The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
Study NCT05644340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speed 4 (Medium speed balancing gas flow)
Description: General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 4 (Medium speed). The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
Study NCT03982030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin 1.5g IV at day 0, day 8-10
Study NCT04705714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frankincense Extract
Description: The phytochemical composition of the volatile components of the extract was identified by GC-MS analysis, Crystal violet assay to test inhibition of biofilm formation by the tested isolates,Light microscope and scanning electron microscope were used to examine the biofilms and they confirmed the reduction of biofilm formation by frankincense extract
Study NCT06231745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.
Study NCT06231745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive compulsive disorder (OCD), panic attacks, anxiety or post-traumatic stress disorder (PTSD).
Study NCT04962594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental formulas (EF)
Description: First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
Study NCT04962594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control formulas (CF)
Description: First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
Study NCT04962594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast feeding (BF)
Description: Exclusive breast feeding up to 4 months
Study NCT05236634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphodiesterase 5 Inhibitors
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Study NCT05688228 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Female Sexual Function Index (FSFI) and self-administrative questionnaires on sexuality just after abortion and repeated at 1, 3 and 6 months
Study NCT05284253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gold microparticles
Description: Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
Study NCT05284253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gold thiosulphate
Description: Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
Study NCT05568004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise
Description: aerobic plus resistance exercise
Study NCT05568004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Only aerobic exercise
Study NCT04954872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Problem Management Plus training (training as usual)
Description: 10-day training on Problem Management Plus.
Study NCT04954872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equip-based Problem Management Plus training
Description: Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
Study NCT05043311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injetion
Study NCT04942600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim Rapid2 Transcranial Magnetic Simulation
Description: A non-invasive method of brain stimulation
Study NCT06410378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patient will receive 20 ml of bupivacaine 0.25 % through Erector Spinae Plane Block approach
Study NCT06410378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: Patient will receive 20 ml of bupivacaine 0.25 % through Serratus Anterior Plane Block approach.
Study NCT04782622 — intervention group
Intervention type: DRUG
Intervention: Apatinib+Camrelizumab
Description: Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
Study NCT05937477 — intervention group
Intervention type: OTHER
Intervention: Fitbit smartwatch
Description: Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
Study NCT05328050 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: observational, data collection
Study NCT06343701 — intervention group
Intervention type: OTHER
Intervention: Implicit motor imagery
Description: Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).
Study NCT06343701 — intervention group
Intervention type: OTHER
Intervention: Explicit motor imagery
Description: In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
Study NCT05236634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Blockers
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Study NCT05236634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Study NCT03175718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incisional Negative Pressure Wound Therapy (INPWT)
Description: A total of 291 patients will be randomized to receive 7 days of Incisional Negative pressure wound dressing. The dressing will be removed 1 week after surgery.
Study NCT03175718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound Dressing
Description: A total of 291 patients will be randomized for standard gauze dressing. This dressing requires no pressure and is applied according to the current standard dressing procedures of the institution. The dressing will be changed every 2-3 days.
Study NCT05852626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redistribution of diabetes care between nurses and physicians
Description: It will be proposed that nurses and physician share the clinical care of patients with type 2 diabetes, with complementing actions
Study NCT05852626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized glycemic target
Description: Define the target of individualized glycemic treatment for patients with the support of a tool on the website, which will encourage the intensification and de-intensification of treatment when appropriate
Study NCT05852626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimum care recomendations
Description: It will be proposed to carry out the minimum necessary assessments that, annually, nurses and physicians must do to ensure the adequacy of quality indicators in the care of diabetes in the PHC
Study NCT05852626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Primary care health teams will follow their rotine care of type 2 diabetes
Study NCT05016323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19042 Capsules
Description: HR19042 Capsules
Study NCT05016323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04069286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Aroeira
Description: Active Group oral Aroeira (Schinus terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks.
Study NCT04069286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20Mg Capsule
Description: Comparator Group omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: 200 mg by IV infusion Q3W, given on cycle day 1.
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS007
Description: 3mg/kg by IV infusion Q3W, given on cycle day 1.
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS015
Description: 600mg by IV infusion Q3W, given on cycle day 1.
Study NCT05498701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Test)
Description: 12.2 mg tafamidis free acid tablet (Test)
Study NCT05498701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine capsule (Reference)
Description: Commercial 20 mg tafamidis meglumine capsule (Reference)
Study NCT06042686 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RF Health MAC Device
Description: Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
Study NCT05607134 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: selected physical and occupational therapy program
Description: The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.
Study NCT05607134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shock Wave
Description: The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.
Study NCT05607134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral magnetic stimulation
Description: The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity.
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: 60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.
Study NCT01179529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair®)
Study NCT06167902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginseng oligopeptide (Ginseng extract）
Description: The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.
Study NCT06167902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The control group was treated with placebo maltodextrin 1.2g/d
Study NCT06410378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: controll group
Description: patient will receive general anesthesia
Study NCT06259162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAG-3 expression / immune checkpoint protein expression
Description: Evaluate the tissue and blood before and after chemotherapy
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: 400mg/m\^2, intravenously, over 30 min on day 1, Q2W.
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
Study NCT06370754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
Study NCT05143359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wharfe and Pederson difficulty index
Description: Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
Study NCT05143359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Winters difficulty index
Description: Efficiency of Winters Difficulty index in extraction of third molars.
Study NCT05916911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glizigen
Description: Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 single doses of intravaginal use and 60 doses of oral solution should be given to each patient.~The intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food.
Study NCT05916911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 placebo single doses of intravaginal use and 60 placebo doses of oral solution should be given to each patient.~The placebo intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The placebo oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food.
Study NCT06344611 — intervention group
Intervention type: OTHER
Intervention: Other
Description: It is an observational study. Subjects will receive the treatment as per institute protocol.
Study NCT05521594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Cytology
Description: Comparison between FNAC and post operative specimen after thyroid surgery
Study NCT05523180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Active ingredients:~Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide
Study NCT05523180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active ingredients:~N/A~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide
Study NCT01283737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBX Putty
Description: OCD of the knee will be treated with DBX Putty